Table 1.
Demographics of selected participants from the ADNI cohort
| Aβ PET negative (n = 58) | Aβ PET positive (n = 60) | P value | |
|---|---|---|---|
| Age, years, median (IQR) | 70.8 (66.5, 75.7) | 73.8 (69.9, 77.4) | 0.14 |
| Clinical diagnosis, n (CU/CI) | 30/28 | 20/40 | 0.04 |
| Female, n (%) | 24 (41.4%) | 26 (43.3%) | 0.98 |
| Years of education, median (IQR) | 18.0 (14.2, 18.0) | 16.0 (14.0, 18.0) | 0.33 |
| APOE-ε4 carriers, n (%) | 15 (25.9%) | 32 (53.3%) | < 0.01 |
| MMSE score, median (IQR) | 29.0 (28.0, 30.0) | 27.5 (24.0, 29.2) | < 0.0001 |
| Florbetapir, global SUVR, median (IQR) | 1.00 (0.954, 1.03) | 1.33 (1.22, 1.46) | < 0.0001 |
| Aβ42/40 IP-MS, median (IQR) | 0.132 (0.128, 0.141) | 0.122 (0.117, 0.127) | < 0.0001 |
| Aβ42/40 Simoa, median (IQR) | 0.050 (0.043, 0.054) | 0.044 (0.040, 0.048) | < 0.01 |
| GFAP, pg/mL, median (IQR) | 113 (80.7, 154) | 164 (125, 223) | < 0.001 |
| P-tau181, pg/mL, median (IQR) | 11.7 (8.2, 17.2) | 18.8 (13.1, 23.0) | < 0.01 |
| NfL, pg/mL, median (IQR) | 23.6 (17.7, 36.1) | 31.5 (24.8, 40.1) | 0.04 |
Data shown as median (IQR; interquartile range) or n (%), as appropriate. Continuous variables were compared using t test and Pearson’s chi-square to compare frequencies of categorical variables between groups. As further explained, Aβ42/40 IP-MS corresponds to the IP-MS assay from Washington University whilst Aβ42/40 Simoa refers to the measurements from the Simoa Neuro 4-plex E assay
Abbreviations: Aβ amyloid-β, CU cognitively unimpaired, CI mild cognitive impairment, MMSE Mini-Mental State Examination, NfL neurofilament light chain, P-tau181 tau phosphorylated at threonine 181, SD standard deviation, SUVR standardized uptake value ratio